(Q36621976)

English

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study

scientific article published on October 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

author name string

M J Allen

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

M Vaughan

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

A Webb

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

S Johnston

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

T Eisen

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

S Bate

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

J Moore

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

R Ahern

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

M E Gore

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

language of work or name

0 references

publication date

1 October 2000

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

83

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

980-985

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363554

30 September 2017

A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363554

30 September 2017

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363554

30 September 2017

Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363554

30 September 2017

The impact of interleukin-2 on survival in renal cancer: a multivariate analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363554

30 September 2017

Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363554

30 September 2017

The use of interferon in renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363554

30 September 2017

Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363554

28 June 2018

Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administrat

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363554

28 June 2018

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363554

28 June 2018

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363554

28 June 2018

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363554

28 June 2018

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363554

20 September 2018

Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10993642

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/10993642

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/10993642

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10993642

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha and survival in renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10993642

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil

1 reference

https://pubmed.ncbi.nlm.nih.gov/10993642

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of continuous infusional 5-fluorouracil (5-FU) and subcutaneous interleukin-2 (IL-2) in metastatic renal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10993642

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://pubmed.ncbi.nlm.nih.gov/10993642

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stratification of risk factors in renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10993642

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/10993642

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1054/BJOC.2000.1418

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Dimensions Publication ID

0 references

release_5orkufx7sbdtffanoh63miwmpe

1 reference

https://api.fatcat.wiki/v0/release/5orkufx7sbdtffanoh63miwmpe

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10993642%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36621976&oldid=2199107887"